Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Molecular Loop Biosciences Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct art unit, which is the same count as the distinct examiners involved in the company's current prosecution. The entire active workload is handled by the examiner, reflecting a point of contact that is not distributed across multiple departments. This structure indicates that the company's current patent efforts are focused on a specific technical subject.
OYEYEMI, OLAYINKA A is the busiest examiner for the company and is responsible for the 1 pending office action. Since the total count of pending actions is 1, this individual's review represents the entirety of the company's active cases at the patent office. The involvement of the distinct art unit means the applicant is dealing with a specific set of departmental standards. There are no other pending matters to provide a comparison of examiner behavior within this specific portfolio.
For a practitioner, the fact that the pending office action is the only active case means that the outcome of this specific matter is the determinant of current prosecution success. The Biotechnology & Pharmaceuticals focus requires adherence to the guidelines of the assigned art unit. Because the prosecution is not spread across different examiners, the applicant can focus their legal strategy on the preferences of OYEYEMI, OLAYINKA A. This centralized interaction simplifies the management of the company's current intellectual property filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OYEYEMI, OLAYINKA A | 1 | 60.4% | +46.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336198 | SCREENING FOR STRUCTURAL VARIANTS | OYEYEMI, OLAYINKA A | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18336198 | SCREENING FOR STRUCTURAL VARIANTS | OYEYEMI, OLAYINKA A | 1681 | §112DP | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMolecular Loop Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olayinka A Oyeyemi has the most, with 1 of Molecular Loop Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
